No Data
No Data
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Jefferies Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $3
Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Wells Fargo Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Cuts Target Price to $2
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership -- Barrons.com